Quantitative Investment Management LLC Invests $1.42 Million in Corteva, Inc. $CTVA

Quantitative Investment Management LLC purchased a new position in shares of Corteva, Inc. (NYSE:CTVAFree Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 16,779 shares of the company’s stock, valued at approximately $1,421,000.

Other large investors have also recently made changes to their positions in the company. GTS Securities LLC raised its stake in shares of Corteva by 21.4% during the 2nd quarter. GTS Securities LLC now owns 3,905 shares of the company’s stock worth $331,000 after purchasing an additional 689 shares during the period. Wedbush Securities Inc. raised its position in Corteva by 8.9% in the second quarter. Wedbush Securities Inc. now owns 6,293 shares of the company’s stock worth $533,000 after acquiring an additional 513 shares during the period. Rational Advisors Inc. purchased a new position in Corteva in the second quarter valued at about $479,000. Greenleaf Trust grew its position in shares of Corteva by 7.4% during the 2nd quarter. Greenleaf Trust now owns 20,511 shares of the company’s stock valued at $1,737,000 after acquiring an additional 1,405 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Corteva by 3.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,903,828 shares of the company’s stock worth $330,615,000 after purchasing an additional 113,564 shares during the last quarter. 81.54% of the stock is owned by hedge funds and other institutional investors.

Corteva Stock Performance

Corteva stock opened at $84.74 on Tuesday. Corteva, Inc. has a 1-year low of $60.53 and a 1-year high of $90.97. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $56.54 billion, a PE ratio of 56.12, a price-to-earnings-growth ratio of 2.58 and a beta of 0.57. The firm’s 50 day simple moving average is $82.81 and its 200 day simple moving average is $80.66.

Corteva (NYSE:CTVAGet Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.24 by $0.06. Corteva had a net margin of 5.66% and a return on equity of 10.18%. The firm had revenue of $6.38 billion during the quarter, compared to analyst estimates of $6.60 billion. During the same period in the previous year, the business earned $2.20 EPS. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. As a group, analysts expect that Corteva, Inc. will post 3.72 earnings per share for the current fiscal year.

Corteva Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be issued a dividend of $0.18 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $0.72 annualized dividend and a dividend yield of 0.8%. Corteva’s payout ratio is presently 47.68%.

Analysts Set New Price Targets

CTVA has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Corteva from $77.00 to $83.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $101.00 price target on shares of Corteva in a research note on Monday, August 3rd. Royal Bank Of Canada restated an “overweight” rating on shares of Corteva in a research note on Friday. Mizuho lifted their target price on shares of Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Finally, Zacks Research cut shares of Corteva from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $91.50.

Read Our Latest Research Report on Corteva

Corteva Profile

(Free Report)

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

Featured Stories

Institutional Ownership by Quarter for Corteva (NYSE:CTVA)

Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.